Literature DB >> 30763761

Molecular characterisation of multidrug-resistant Klebsiella pneumoniae belonging to CC258 isolated from outpatients with urinary tract infection in Brazil.

Paola Aparecida Alves Azevedo1, João Pedro Rueda Furlan1, Guilherme Bartolomeu Gonçalves1, Carolina Nogueira Gomes1, Rafael da Silva Goulart2, Eliana Guedes Stehling1, André Pitondo-Silva3.   

Abstract

OBJECTIVES: This study characterised 48 Klebsiella pneumoniae isolates from outpatients with urinary tract infection in the micro-region of Ribeirão Preto, located in southeastern Brazil.
METHODS: The isolates were identified by conventional biochemical and phenotypic tests and were confirmed as K. pneumoniae using a MALDI-TOF VITEK® MS system. Antimicrobial susceptibility testing was performed by the disk diffusion method as recommended by the Clinical and Laboratory Standards Institute (CLSI) using 38 different antibiotic discs. Fifteen β-lactamase and ten virulence genes were investigated by PCR. Clonal relationships among the isolates were determined by enterobacterial repetitive intergenic consensus PCR (ERIC-PCR) and multilocus sequence typing (MLST).
RESULTS: Of the 48 isolates, 29 (60.4%) were classified as multidrug-resistant. A total of 46 β-lactamase genes were found in 27 (56.3%) of the isolates, with blaKPC being the most prevalent distributed in 18 isolates (37.5%). Moreover, 73 virulence genes were found in 30 isolates (62.5%). ERIC-PCR results showed high genetic diversity among the isolates. Twelve different sequence types (STs) were found by MLST (ST14, ST17, ST101, ST200, ST334, ST433, ST437, ST442, ST449, ST502, ST1246 and ST2729), with ST2729 being described for the first time in this study. Seven STs were grouped in clonal complex 258 (CC258) frequently associated with various resistance and virulence genes.
CONCLUSIONS: These results raise concern about epidemiological surveillance related to colonisation of patients discharged from hospitals in order to prevent both the occurrence and spread of resistant bacterial infections in the community.
Copyright © 2019 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Klebsiella pneumoniae; MDR; MLST; Outpatients; UTI; Virulence genes

Mesh:

Substances:

Year:  2019        PMID: 30763761     DOI: 10.1016/j.jgar.2019.01.025

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.035


  4 in total

1.  Characterization of multidrug-resistant and virulent Klebsiella pneumoniae strains belonging to the high-risk clonal group 258 (CG258) isolated from inpatients in northeastern Brazil.

Authors:  Rafael Nakamura-Silva; Mariana Oliveira-Silva; João Pedro Rueda Furlan; Eliana Guedes Stehling; Carlos Eduardo Saraiva Miranda; André Pitondo-Silva
Journal:  Arch Microbiol       Date:  2021-06-10       Impact factor: 2.552

2.  Multidrug-resistant Klebsiella pneumoniae: a retrospective study in Manaus, Brazil.

Authors:  Rafael Nakamura-Silva; Louise Cerdeira; Mariana Oliveira-Silva; Karen Regina Carim da Costa; Elder Sano; Bruna Fuga; Quézia Moura; Fernanda Esposito; Nilton Lincopan; Kelly Wyres; André Pitondo-Silva
Journal:  Arch Microbiol       Date:  2022-03-04       Impact factor: 2.667

3.  Genomic insights into the diversity, virulence and resistance of Klebsiella pneumoniae extensively drug resistant clinical isolates.

Authors:  Amy H Y Lee; William F Porto; Célio de Faria; Simoni C Dias; Sérgio A Alencar; Derek J Pickard; Robert E W Hancock; Octavio L Franco
Journal:  Microb Genom       Date:  2021-08

4.  Within patient genetic diversity of blaKPC harboring Klebsiella pneumoniae in a Colombian hospital and identification of a new NTEKPC platform.

Authors:  Deisy Abril; Erika Vergara; Diana Palacios; Aura Lucía Leal; Ricaurte Alejandro Marquez-Ortiz; Johana Madroñero; Zayda Lorena Corredor Rozo; Zandra De La Rosa; Carlos A Nieto; Natasha Vanegas; Jorge A Cortés; Javier Escobar-Perez
Journal:  Sci Rep       Date:  2021-11-01       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.